TY - JOUR AU - Adderley, Helen AU - Ackermann, Christoph Jakob AU - Califano, Raffaele PY - 2019 TI - Erlotinib plus bevacizumab for EGFR -mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line? JF - Annals of Translational Medicine; Vol 7, Supplement 8 (December 31, 2019): Annals of Translational Medicine Y2 - 2019 KW - N2 - EGFR tyrosine kinase inhibitors (TKIs) represent the standard of care for first-line treatment for patients with advanced EGFR mutant non-small cell lung cancer (NSCLC) with superiority in overall response rate (ORR), progression free survival (PFS) and quality of life compared to platinum-based chemotherapy (ChT) (1). UR - https://atm.amegroups.org/article/view/30081